Cargando…

Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl

The intracellular and tissue balance of oxidant and antioxidant forces is a potential therapeutic target for a variety of agents in the treatment of complications due to chronic disease including diabetes mellitus and hypertension. There are a myriad of processes controlled at the level of genes, tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCullough, Peter A, Ali, Sajid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392144/ https://www.ncbi.nlm.nih.gov/pubmed/22787387 http://dx.doi.org/10.2147/DDDT.S26714

Ejemplares similares

Bardoxolone methyl: drug development for diabetic kidney disease
por: Kanda, Hironori, et al.
Publicado: (2020)

Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
por: Rojas-Rivera, Jorge, et al.
Publicado: (2012)

Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)
por: Nangaku, Masaomi, et al.
Publicado: (2020)

Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD
por: Lewis, James H., et al.
Publicado: (2020)

Anticholestatic Effect of Bardoxolone Methyl on Hepatic Ischemia-reperfusion Injury in Rats
por: Kim, Joohyun, et al.
Publicado: (2020)

Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease
por: Sun, Qi, et al.
Publicado: (2021)

Bardoxolone Methyl Prevents Mesenteric Fat Deposition and Inflammation in High-Fat Diet Mice
por: Dinh, Chi H. L., et al.
Publicado: (2015)

Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function
por: Nagasu, Hajime, et al.
Publicado: (2019)

Bardoxolone methyl ameliorates osteoarthritis by inhibiting osteoclastogenesis and protecting the extracellular matrix against degradation
por: Yang, Ruijia, et al.
Publicado: (2023)

Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study
por: Nangaku, Masaomi, et al.
Publicado: (2022)

Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties
por: Wang, Yan-Yang, et al.
Publicado: (2014)

Bardoxolone methyl inhibits the infection of rabies virus via Nrf2 pathway activation in vitro
por: Chi, Ying Lin, et al.
Publicado: (2023)

In vitro study on effect of bardoxolone methyl on cisplatin-induced cellular senescence in human proximal tubular cells
por: Kurosaki, Yoshifumi, et al.
Publicado: (2022)

Bardoxolone conjugation enables targeted protein degradation of BRD4
por: Tong, Bingqi, et al.
Publicado: (2020)

Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells
por: Wang, Yan-Yang, et al.
Publicado: (2015)

Bardoxolone-Methyl Prevents Oxidative Stress-Mediated Apoptosis and Extracellular Matrix Degradation in vitro and Alleviates Osteoarthritis in vivo
por: Pang, Zhiying, et al.
Publicado: (2021)

Repeated glucose spikes and insulin resistance synergistically deteriorate endothelial function and bardoxolone methyl ameliorates endothelial dysfunction
por: Ogiso, Kazuma, et al.
Publicado: (2022)

Bardoxolone-Methyl (CDDO-Me) Impairs Tumor Growth and Induces Radiosensitization of Oral Squamous Cell Carcinoma Cells
por: Hermann, Cornelius, et al.
Publicado: (2021)

Bardoxolone Methyl Ameliorates Myocardial Ischemia/Reperfusion Injury by Activating the Nrf2/HO-1 Signaling Pathway
por: Huang, Anwu, et al.
Publicado: (2023)

The Effects of Two Nrf2 Activators, Bardoxolone Methyl and Omaveloxolone, on Retinal Ganglion Cell Survival during Ischemic Optic Neuropathy
por: Chien, Jia-Ying, et al.
Publicado: (2021)

Bardoxolone Methyl Ameliorates Compression-Induced Oxidative Stress Damage of Nucleus Pulposus Cells and Intervertebral Disc Degeneration Ex Vivo
por: Tian, Yueyang, et al.
Publicado: (2022)

46 Bardoxolone-methyl Microparticles Ameliorate Immune Dysfunction Following Burn and Inhalation Injury Through the NRF2/KEAP1 Axis
por: Seim, Roland F, et al.
Publicado: (2022)

Bardoxolone Methyl Prevents Fat Deposition and Inflammation in Brown Adipose Tissue and Enhances Sympathetic Activity in Mice Fed a High-Fat Diet
por: Dinh, Chi H. L., et al.
Publicado: (2015)

Bardoxolone Methyl Displays Detrimental Effects on Endothelial Bioenergetics, Suppresses Endothelial ET-1 Release, and Increases Endothelial Permeability in Human Microvascular Endothelium
por: Szczesny-Malysiak, Ewa, et al.
Publicado: (2020)

Primary Care Detection of Chronic Kidney Disease in Adults with Type-2 Diabetes: The ADD-CKD Study (Awareness, Detection and Drug Therapy in Type 2 Diabetes and Chronic Kidney Disease)
por: Szczech, Lynda A., et al.
Publicado: (2014)

Renoprotection and the Bardoxolone Methyl Story – Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for Renoprotective Agents
por: Onuigbo, Macaulay
Publicado: (2013)

Keap1-Nrf2 signaling activation by Bardoxolone-methyl ameliorates high glucose-induced oxidative injury in human umbilical vein endothelial cells
por: Yang, Jing-Lei, et al.
Publicado: (2020)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
por: Khurana, Namrata, et al.
Publicado: (2020)

Analgesic Effects of Fisetin, Peimine, Astaxanthin, Artemisinin, Bardoxolone Methyl and 740 Y-P and Their Influence on Opioid Analgesia in a Mouse Model of Neuropathic Pain
por: Ciapała, Katarzyna, et al.
Publicado: (2023)

A Point Mutation at C151 of Keap1 of Mice Abrogates NRF2 Signaling, Cytoprotection in Vitro, and Hepatoprotection in Vivo by Bardoxolone Methyl (CDDO-Me)
por: Gatbonton-Schwager, Tonibelle, et al.
Publicado: (2023)

Visual Profile of Children who Passed or Failed the UK School Vision Screening Protocol
por: McCullough, Sara, et al.
Publicado: (2019)

Chronic kidney disease patients who smoke have higher serum phosphorus
por: dos Santos, Geuza Dutra, et al.
Publicado: (2018)

Predictors of Diabetic Retinopathy in Patients with Type 2 Diabetes Who Have Normoalbuminuria
por: Karoli, R, et al.
Publicado: (2013)

Endothelial Cell Autoantibodies in Predicting Declining Renal Function, End-Stage Renal Disease, or Death in Adult Type 2 Diabetic Nephropathy
por: Zimering, Mark B., et al.
Publicado: (2014)

Kinetics of Urinary Cell Cycle Arrest Markers for Acute Kidney Injury Following Exposure to Potential Renal Insults
por: Ostermann, Marlies, et al.
Publicado: (2018)

Therapeutic effects of C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO-Me; bardoxolone methyl) on radiation-induced lung inflammation and fibrosis in mice
por: Wang, Yan-Yang, et al.
Publicado: (2015)

Cardiorenal Nexus: A Review With Focus on Combined Chronic Heart and Kidney Failure, and Insights From Recent Clinical Trials
por: McCullough, Peter A., et al.
Publicado: (2022)

Chronic kidney disease with comorbid cardiac dysfunction exacerbates cardiac and renal damage
por: Liu, Shan, et al.
Publicado: (2017)

Rate of major adverse renal or cardiac events with iohexol compared to other low osmolar contrast media during interventional cardiovascular procedures
por: McCullough, Peter A., et al.
Publicado: (2018)

ICU patients treated with RRT for AKI who have chronic kidney disease have better 1-year outcome compared with patients with better kidney function
por: De Corte, W, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3t5chc701rjjsloo1cncm3prrf